The estimated Net Worth of Mary Beth Dooley is at least $21.3 mil dollars as of 2 April 2024. Mary Dooley owns over 188 units of Synlogic Inc stock worth over $21,019 and over the last few years Mary sold SYBX stock worth over $325.
Mary has made over 1 trades of the Synlogic Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Mary sold 188 units of SYBX stock worth $325 on 2 April 2024.
The largest trade Mary's ever made was selling 188 units of Synlogic Inc stock on 2 April 2024 worth over $325. On average, Mary trades about 188 units every 0 days since 2024. As of 2 April 2024 Mary still owns at least 15,231 units of Synlogic Inc stock.
You can see the complete history of Mary Dooley stock trades at the bottom of the page.
Mary's mailing address filed with the SEC is C/O SYNLOGIC, INC., 301 BINNEY STREET, SUITE 402, CAMBRIDGE, MA, 02142.
Over the last 7 years, insiders at Synlogic Inc have traded over $330,991 worth of Synlogic Inc stock and bought 17,000 units worth $31,190 . The most active insiders traders include Forest Baskett, Scott D Sandell y Anthony A. Jr. Florence. On average, Synlogic Inc executives and independent directors trade stock every 132 days with the average trade being worth of $7,257. The most recent stock trade was executed by Mary Beth Dooley on 2 April 2024, trading 188 units of SYBX stock currently worth $325.
at synlogic, we are dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. using our synthetic biotics platform, we are engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. we can deliver these synthetic biotics™ orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. we also aim to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. we can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. our lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (ucd) and phenylketonuria (pku). we are also hard at work on synthetic biotics™ to address more pre
Synlogic Inc executives and other stock owners filed with the SEC include: